Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1990-09-27
1993-01-12
Kepplinger, Esther L.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 71, 435 72, 435 79, 435 792, 436518, 436 64, 436813, G01N 33574, G01N 3353, G01N 3348
Patent
active
051790009
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to a method for assaying basic fetoprotein and an assay kit therefor.
BACKGROUND ART
Basic fetoprotein (referrred to hereinafter as "BFP"), which is a known basic protein, has been found by one of the inventors of this application in serum, intestine and brain tissues of human fetus. It has been particularly called basic fetoprotein since it is basic in contrast to the known acidic fetoprotein. Furthermore, one of the inventors has established a radioimmunoassay system of said protein and found that the assay of said protein in serum would help to diagnose cancer and judge its condition and therapeutical effect thereon. In particular, it has been found that said fetoprotein is useful to examine the presence of cancer, differing from alpha-fetoprotein (referred to hereinafter as "AFP") which is useful to diagnose cancer of a particular organ.
The following references (1) to (7) may be cited for the above prior findings.
(1) Ishii, M. et al.: Studies on Feto-Neoplastic Antigen. Proceedings of The Japanese Cancer Association, The 34th Annual Meeting, p.173 (1975).
(2) Ishii, M.: Studies on novel basic fetoprotein found in various malignant tumors. Igaku no Ayumi (The Stride of Medicine), 100(3), 344-346 (1977).
(3) Ishii, M.: Basic fetoprotein. Igaku no Ayumi (The Stride of Medicine), 106(5), 273-281 (1978).
(4) Ishii, M.: A new carcinoembryonic protein characterized by basic property. Scand. J. Immunol., 8(Suppl.8), 611-620 (1978).
(5) Ishii, M.: Characterization of basic fetoprotein and clinical usefulness of BFP for immunodiagnosis of human cancer. Carcino-Embryonic Proteins. Chemistry, Biology, Clinical Applications, Vol. 1, Lehmann, F.-G. (ed.), Elsevier/North-Holland Biomedical Press, Amsterdam, 333-340 (1979).
(6) Ishii, M., Nishimura, K., Hattori, M., Kanda, Y. and Ishihara, A.: Postoperative surveillance in patients with stomach cancer and monitoring of immuno-and polychemotherapy in patients with leukemia by basic fetoprotein. Carcino-Embryonic Proteins. Chemistry, Biology, Clinical Applications, Vol. 2, Lehmann, F.-G. (ed.), Elsevier/North-Holland Biomedical Press, Amsterdam, 603-606 (1979).
(7) Ishii, M.: Clinical usefulness of basic fetoprotein for immunodiagnosis of human cancer. Compendium of Assay for Immunodiagnosis of Human Cancer. Development in Cancer Research, Herberman, R. B. (ed.), Vol. 1, Elsevier/North-Holland Biomedical Press, New York, 45-50 (1979).
(8) PROCEEDINGS, Sixth Annual Meeting of the Tumor Marker, Program Abstract, p.111, Oct. 20 (1986), Sapporo.
(9) PROCEEDINGS, Sixth Annual Meeting of the Tumor Marker, p.248-250, Oct. 20 (1986). Sapporo.
Since basic fetoprotein is present in the serum of cancer patients in a trace amount, it is necessary to establish a highly sensitive assay system to determine it. RIA and EIA methods have been mainly developed therefor. Detailed descriptions of the RIA method are found in the references (3) to (7) as cited above. Detailed descriptions of the EIA method are found in the following references (10) and (11).
(10) Ishii, M. et al.: Basic fetoprotein, present clinical function test--enforcement and interpretation thereof. Nippon Rinsho 37, 1536-1539 (1979).
(11) Ishii, M.: Basic fetoprotein: Rinsho Kensa 24, (8), 931-936 (1980).
Subsequently, the inventors have succeeded in obtaining monoclonal anti-basic fetoprotein antibodies. Preparation and evaluation of said monoclonal antibodies are described in the following reference (12).
(12) Ishii, M. et al.: Production of Monoclonal Anti-Basic Fetoprotein (BFP) and Usefulness of Monoclonal Anti-BFP for Immuno-diagnosis of Human Cancer, Tumor Research, Vol. 18, (Special Issue),1983 p75-86.
The reaction specificities for basic fetoprotein of the monoconal antibodies thus obtained were examined by the EIA and MO (Micro-Ouchterlony) methods. Consequently, it was found that there are at least three different antigenic determinants on the basic fetoprotein molecule and that the monoclonal antibodies might be classified into three types corresponding to each ant
REFERENCES:
patent: 4152410 (1979-05-01), Ishii
patent: 4376110 (1983-03-01), David et al.
patent: 4692404 (1987-09-01), Ashihara et al.
patent: 4868106 (1989-09-01), Ito et al.
Nagata et al., "The Role of Basic Fetoprotein in the Field of Urology, with Special Reference to its Value as a Testicular Marker", Hiriyokika Kiyo; 28(10): 1213-1219-Abstract 1982.
Nakazono et al., Nishinihon Journal of Urology, vol. 49, No. 6, 1987, "Evaluation of Tumor Markers in Urogenital Malignancies", (1745-1749).
Chemical Abstracts, vol. 98, May 23-Jun. 6 (1983) p. 316.
Ishii Masaru
Seino Yuko
Kepplinger Esther L.
Nippon Kayaku Kabushiki Kaisha
Scheiner Toni R.
LandOfFree
Method for assaying basic fetoprotein in urine and assay kit the does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for assaying basic fetoprotein in urine and assay kit the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for assaying basic fetoprotein in urine and assay kit the will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1219553